Your browser is no longer supported. Please, upgrade your browser.
Settings
ABBV AbbVie Inc. daily Stock Chart
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E18.49 EPS (ttm)3.49 Insider Own0.10% Shs Outstand1.63B Perf Week-3.73%
Market Cap105.24B Forward P/E11.31 EPS next Y5.71 Insider Trans-26.54% Shs Float1.63B Perf Month-2.60%
Income5.72B PEG1.14 EPS next Q1.19 Inst Own71.90% Short Float2.95% Perf Quarter3.41%
Sales24.75B P/S4.25 EPS this Y185.20% Inst Trans1.97% Short Ratio6.02 Perf Half Y16.62%
Book/sh3.47 P/B18.59 EPS next Y18.66% ROA10.00% Target Price70.78 Perf Year4.73%
Cash/sh4.91 P/C13.15 EPS next 5Y16.25% ROE119.80% 52W Range44.16 - 68.12 Perf YTD12.07%
Dividend2.28 P/FCF25.67 EPS past 5Y3.50% ROI16.90% 52W High-5.56% Beta1.50
Dividend %3.53% Quick Ratio1.60 Sales past 5Y7.90% Gross Margin78.60% 52W Low45.67% ATR0.97
Employees28000 Current Ratio1.80 Sales Q/Q17.80% Oper. Margin35.00% RSI (14)39.33 Volatility1.87% 1.40%
OptionableYes Debt/Eq6.71 EPS Q/Q17.90% Profit Margin23.10% Rel Volume0.63 Prev Close64.51
ShortableYes LT Debt/Eq6.62 EarningsJul 29 BMO Payout63.30% Avg Volume7.97M Price64.33
Recom2.30 SMA20-3.01% SMA500.24% SMA2009.12% Volume2,722,747 Change-0.28%
Jun-08-16Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-06-16Initiated Societe Generale Sell $47
Mar-15-16Initiated Deutsche Bank Hold $63
Feb-23-16Upgrade Citigroup Neutral → Buy
Dec-01-15Downgrade Barclays Overweight → Equal Weight $73 → $72
Nov-02-15Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-23-15Reiterated UBS Buy $81 → $78
Sep-28-15Upgrade Citigroup Sell → Neutral
Jul-22-15Initiated Sun Trust Rbsn Humphrey Buy
Jun-17-15Initiated Piper Jaffray Overweight
Jun-08-15Reiterated Jefferies Buy $86 → $90
May-28-15Resumed Morgan Stanley Equal-Weight $72
May-27-15Resumed JP Morgan Overweight $75
Jan-06-15Reiterated UBS Buy $72 → $76
Nov-26-14Reiterated Argus Buy $65 → $85
Nov-14-14Initiated Deutsche Bank Buy $80
Jul-28-14Upgrade UBS Neutral → Buy $57 → $67
Jun-24-14Reiterated Argus Buy $59 → $65
Jan-06-14Reiterated UBS Neutral $46 → $56
Oct-29-13Reiterated Argus Buy $52 → $59
Aug-30-16 09:50AM  7 Healthy Dividend Stocks for Quality and Security at Kiplinger
08:00AM  AbbVie to Present at the Morgan Stanley Global Healthcare Conference PR Newswire
Aug-29-16 09:49AM  Better Buy: GlaxoSmithKline plc vs. AbbVie at Motley Fool
Aug-27-16 12:01AM  [$$] The 10 Best Dividend Stocks at Barrons.com
Aug-26-16 03:57PM  AbbVie Inc (ABBV) Expected To Launch Zinbryta In The US This Month at Insider Monkey
10:04AM  AbbVie Expects Investigational Drug Elagolix to Be a Blockbuster
08:04AM  Could Zinbryta Become a Novel Immunomodulatory Therapy for MS?
Aug-25-16 11:04AM  AbbVie Launched Zinbryta in the US in August
10:04AM  How Late-Stage Asset Rova-T Could Become a Leading Therapy
08:45AM  Major Pharma Short Interest Faces Significant Drop at 24/7 Wall St.
08:04AM  How AbbVie Expects BCL-2 Inhibitor Venclexta to Prove Effective
Aug-24-16 12:10PM  Why OraSure Technologies, Inc is Jumping Today at Motley Fool
11:04AM  Litigation Has Teva Pharmaceuticals Copaxone 40 mg All Tied Up
11:04AM  Imbruvica Continues to Report Better-than-Expected Sales in 2016
10:04AM  How Humira-Related Uncertainty Has Affected AbbVies Valuations
08:04AM  AbbVie Expects to Commercialize Selective JAK1 Inhibitor ABT-494
Aug-23-16 03:04PM  How AbbVie Expects Risankizumab to Be a Transformative Therapy
02:04PM  What Are Analysts Recommendations for AbbVie in 2016?
11:47AM  How AbbVies Valuation Multiples Compare with Its Peers
12:09AM  [$$] Pfizers Medivation Deal Latest in Long Line of Similar Acquisitions at The Wall Street Journal
Aug-22-16 01:24PM  [$$] Pfizer makes $14bn bet on cancer drugmaker Medivation at Financial Times
12:22PM  [$$] Pfizer's Medivation Deal Latest in Long Line of Similar Acquisitions at The Wall Street Journal
09:05AM  Can Allergan Generics Boost Teva Pharmaceuticals 2016 Revenues?
08:22AM  Johnson & Johnson Could Become the First Company to Reach a $1 Trillion Valuation at Motley Fool
07:20AM  [$$] Pfizer agrees $14bn takeover of Medivation at Financial Times
Aug-21-16 08:02PM  Harvard Explains The Health Effects Of Medical And Recreational Use Of Marijuana
06:45AM  Here's the Best Dividend Stock in Big Pharma at Motley Fool
Aug-19-16 09:30AM  Zacks Value Investor Highlights: AbbVie, Berry Plastics, Hawaiian Holdings, Toll Brothers and Pulte
08:08AM  3 Cheap Dividend Stocks You Can Buy Right Now at Motley Fool
07:00AM  No Pain, Potential for Lots of Gain at Morningstar
Aug-18-16 04:21PM  10 Highest Healthcare Dividend Stocks at Motley Fool
02:08PM  Gilead May Be Better Off Splitting Itself in Two, Analysts Say
09:04AM  Ozanimod May Prove to Be a Strong Growth Driver for Celgene
Aug-17-16 06:03PM  How Value Investors Can Buy Growth
03:24PM  Gilead Sciences: Still Dominating Hepatitis C But at Barrons.com
03:06PM  Better Buy: AbbVie Inc. vs. Eli Lilly & Co. at Motley Fool
06:50AM  J&J's (JNJ) Depression Treatment Esketamine Gets BTD
Aug-15-16 01:05PM  Credit Suisse Issues Top Pharma Picks in Bull/Bear Upside Analysis at 24/7 Wall St.
Aug-12-16 01:09PM  Analysts Recommendations for Celgene and Its Peers in 2016
01:09PM  How Do Celgenes Valuation Multiples Compare to Its Peers?
01:04PM  ABBVIE INC. Financials
11:41AM  Prices for These 4 Top-Selling Prescription Drugs Have More Than Doubled Since 2010 at Motley Fool
09:30AM  The Zacks Analyst Blog Highlights: Regeneron, BioMarin, AbbVie, Amgen and Biogen
06:30AM  Analysts: Gilead Should Divide Itself and Conquer
Aug-11-16 05:30PM  Biotech Stock Roundup: Earnings in Focus, AbbVie Takes Steps to Block Humira Copycat
09:06AM  Understanding Growth Contributors for Pfizer
Aug-10-16 09:05AM  Major Pharma Short Interest Slides at 24/7 Wall St.
05:50AM  [$$] Drugmakers hooked on $10bn opioid habit at Financial Times
Aug-08-16 04:03PM  Stocks Retreat From Records as Health Care Slumps
02:50PM  Stocks Fall as Health Care Selloff Counters Energy Rally
10:05AM  Jefferies Makes Another Big Summer Change to Its Franchise Picks List at 24/7 Wall St.
Aug-06-16 12:26AM  [$$] AbbVie Files Patent Suit Over Amgens Copy of Humira at The Wall Street Journal
Aug-05-16 06:47PM  Elliott Associates sues AbbVie over failed bid for Shire
05:59PM  [$$] Elliott Sues AbbVie Over Failed Inversion Deal With Shire at The Wall Street Journal
04:48PM  [$$] AbbVie Sues Amgen Over Humira at The Wall Street Journal
02:38PM  AbbVie (ABBV) Stock Up, Sues Amgen to Block Humira Copycat
12:27PM  ABBVIE INC. Files SEC form 10-Q, Quarterly Report
11:32AM  AbbVie Sues Amgen to Fend Off Copy of Blockbuster Humira
10:20AM  Jefferies Keeps Red-Hot Dividend Pharmaceutical Stock as Top Sector Pick at 24/7 Wall St.
Aug-04-16 06:42PM  Healthcare Dividend Growth Stocks: Part 1
02:34PM  ETFs with exposure to AbbVie, Inc. : August 4, 2016
11:30AM  NBIX: NDA for Valbenazine in Tardive Dyskinesia Set to be Filed; Data From Tourette Syndrome Trials at Year End
06:00AM  'Mad Money' Lightning Round: I'm Still With Opko Health
02:25AM  Disease With $78 Billion Cost Draws Drugmakers to Womens Health at Bloomberg
Aug-03-16 03:39PM  A Look at Mallinckrodts Operating Segments
11:21AM  AbbVie, Inc. :ABBV-US: Earnings Analysis: Q2, 2016 By the Numbers : August 3, 2016
Aug-02-16 09:42AM  Investors now penalize companies addicted to share buybacks at MarketWatch
07:36AM  AbbVie Is Headed Even Higher -- Here's How to Trade It Now
Aug-01-16 05:05PM  Portfolio Roundup: Humira Helps Buoy AbbVie Shares at TheStreet
04:36PM  Express Scripts Says Still Reviewing Gilead Drugs at Bloomberg
03:21PM  Top Research Reports for Morgan Stanely, Union Pacific & AbbVie
10:10AM  Company News for August 01, 2016
10:00AM  What Awaits MNK & Other Drug Stocks this Earnings Season?
07:45AM  Gilead Sciences Has No Cure in Sight for Increasing Competition
Jul-29-16 04:38PM  AbbVie, Merck Beat Earnings Estimates, But Sanofi Lags
04:05PM  AbbVie Shares Rise on Revenue Jump at TheStreet
03:09PM  AbbVie Is Still Pointed Up, for Now
01:23PM  Trending Tickers: BUD, ABBV, SRCL, EXPE
01:15PM  Abbvie Plans to Defend Humira, Sees Upside in Oncology and Hep C Treatments
11:58AM  Edited Transcript of ABBV earnings conference call or presentation 29-Jul-16 1:00pm GMT
11:29AM  M&A Smorgasbord for NextEra, Plus Earnings Results from Exxon, AbbVie, 2 Other Companies at Insider Monkey
10:44AM  AbbVie (ABBV) Beats on 2Q Earnings, Revenues, Ups View
10:13AM  [$$] AbbVie Results Boosted by Humira, Pipeline Growth at The Wall Street Journal
09:55AM  Q2 GDP Disappoints, Q2 Earnings Mixed Ahead of Bell: XOM, CVX, UPS, ABBV, BCS
09:32AM  Drugmaker AbbVie bumps up profit forecast on strong Humira sales
09:05AM  How AbbVie Won Big on Earnings at 24/7 Wall St.
09:00AM  AbbVie Inc Earnings Call scheduled for 9:00 am ET today
08:58AM  AbbVie (ABBV) Tops 2Q Earnings & Revenue Estimates
08:45AM  Morning Movers: Exxon Sinks on Earnings Miss; AbbVie Gains at Barrons.com
08:40AM  5 Things You Must Know Before the Market Opens Friday
08:19AM  Investors Cheer AbbVie's Q2 Numbers, Forecast
08:15AM  Jefferies Makes Key Changes to Top Energy Stocks in Franchise Picks Portfolio at 24/7 Wall St.
07:57AM  AbbVie (ABBV) Stock Up After Q2 Beat
07:55AM  AbbVie profit and revenue beat expectations, raises 2016 guidance at MarketWatch
07:51AM  AbbVie revenue jumps 17.8 pct on higher demand for drug Humira
07:49AM  AbbVie beats Street 2Q forecasts
07:44AM  ABBVIE INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:39AM  AbbVie Profit Beat Estimates as Sales of Flagship Humira Soar at Bloomberg
07:38AM  AbbVie Reports Second-Quarter 2016 Financial Results PR Newswire
07:07AM  Q2 2016 AbbVie Inc Earnings Release - Before Market Open
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for adults with genotype 1 chronic hepatitis, including those with compensated cirrhosis. It also provides Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent respiratory syncytial virus infection in high risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and endometriosis and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, and Niaspan to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has strategic collaboration with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; Ablynx NV; Galapagos NV; and Alvine Pharmaceuticals, Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schumacher Laura JExecutive Vice PresidentJun 24Option Exercise27.62186,1065,140,971380,244Jun 28 05:47 PM
Schumacher Laura JExecutive Vice PresidentJun 24Sale60.03186,10611,171,173194,138Jun 28 05:47 PM
GONZALEZ RICHARD AChairman of the Board and CEOJun 02Sale63.82285,95318,249,712338,421Jun 03 05:26 PM
GONZALEZ RICHARD AChairman of the Board and CEOMay 11Sale63.8039,0002,488,200338,421May 13 05:11 PM
HURWICH THOMAS A.VP, ControllerMay 10Option Exercise27.296,000163,74068,204May 12 05:44 PM
ALBAN CARLOSEVP, Commercial OperationsMay 10Sale63.5247,4383,013,262149,444May 12 05:39 PM
HURWICH THOMAS A.VP, ControllerMay 10Sale63.596,000381,54162,204May 12 05:44 PM
Schumacher Laura JExecutive Vice PresidentMar 08Sale56.0925,0001,402,341194,138Mar 08 05:23 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 05Option Exercise22.943,40077,9985,143Feb 09 05:13 PM